/Companies

Humane Genomics

YC S21

New York City, US · Founded 2019 · 5 employees · 14 known investors

Find your way into Humane Genomics

Sign up to see every warm intro you have to Humane Genomics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Humane Genomics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Humane Genomics develops oncolytic viral therapies designed to selectively target and kill cancer cells using engineered RNA viruses, particularly Vesicular Stomatitis Virus. The company leverages a computational platform for viral genome design and engineering to create cancer treatments with improved safety, efficacy, and manufacturing efficiency.

Founders & leadership· Y Combinator alumni (S21)

Humane Genomics was founded in 2019 by Peter Weijmarshausen and Chad Moles.

PWPeter Weijmarshausen
Peter WeijmarshausenCEO / Co-founderPeter Weijmarshausen is a founder and former CEO of Shapeways who has built software and product teams across multiple companies. He holds a BSc in Applied Physics and is now developing a platform for artificial virus-based cancer therapeutics.
CMChad Moles
Chad MolesCo-founder and Chief Science OfficerChad Moles has worked in biotech and public health, with education from Columbia and Tulane. He is building a platform to engineer viruses for cancer therapy applications.

Investors · 14

2048 Ventureslisted by 2048 VenturesNew York · $500K – $3M

How we know: 2048 Ventures's portfolio page · a partner's Signal profile · the VCSheet dataset · open dataset · 5k.vc investor directory · Y Combinator's founder network · Not right? Tell us

Community Access Fundreported

How we know: Y Combinator's founder network · Not right? Tell us

SAV (Scale Asia Ventures)reportedPalo Alto

How we know: Y Combinator's founder network · Not right? Tell us

Zachary Ginsburg FundsreportedLynnwood

How we know: Y Combinator's founder network · Not right? Tell us

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 7

1849 bio1849 bio engineers microorganisms to make metal extraction from low-grade copper and gold ores economically viable for mining operations. The company applies advanced bioengineering techniques to develop microbes capable of processing ore types that existing biomining processes cannot handle, targeting the hundreds of billions of dollars in copper currently considered uneconomical to extract.
TareBioTareBio operates a platform for developing personalized and population-level vaccines against cancer and infectious diseases by analyzing immune cells already responding to a disease and reverse-engineering the antigens that activate them. The company works in the biotechnology and vaccine development space.
Ginkgo BioworksGinkgo Bioworks builds autonomous labs that accelerate bioengineering for applications in pharmaceutical, agricultural, and industrial biotechnology. The company serves biopharma, agritech, and industrial biotech companies seeking to engineer organisms at scale.
InvertInvert provides infrastructure and intelligence software that connects bioprocess equipment and data sources for pharmaceutical and biologics companies, enabling faster process development and manufacturing through integrated data platforms and digital twin capabilities.
Read on Scientific AmericanScientific American is a media organization that publishes research and ideas across science, health, technology and society through multiple formats including print, web, video, and podcasts. Founded in 1845, it reaches over 20 million people monthly and maintains editorial independence while providing trustworthy science communication and commentary.
Engage BioEngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.
Pano AIPano develops artificial intelligence and machine learning technology solutions to help utility companies and fire agencies detect and manage wildfire threats. The company serves emergency managers and professionals in the utility and fire industries seeking to protect communities from wildfires.

Companies working in the same space as Humane Genomics.

Legal entities · 1

corporate structure
Humane Genomics Inc.

In the news

Frequently asked questions

What does Humane Genomics do?
Humane Genomics develops oncolytic viral therapies designed to selectively target and kill cancer cells using engineered RNA viruses, particularly Vesicular Stomatitis Virus. The company leverages a computational platform for viral genome design and engineering to create cancer treatments with improved safety, efficacy, and manufacturing efficiency.
Who founded Humane Genomics?
Humane Genomics was founded by Peter Weijmarshausen, Chad Moles in 2019.
Who are Humane Genomics's investors?
Humane Genomics's investors include 2048 Ventures, Gaingels, Humba Ventures, Leo Capital Ventures, LifeX Ventures, Mana Ventures, Red Beard Ventures, Union Square Ventures (USV) and 6 more.
Where is Humane Genomics headquartered?
Humane Genomics is headquartered in New York City, US.